Innate Pharma S.A.

Paris Stock Exchange:IPH.PA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

💉 Vaccines

Location

France

Market Cap

USD 170.25 M

Share Price

USD 1.83

Avg Daily Volume

106,534

Change (1 day)

-3.40%

Change (1 year)

-16.90%

Change (YTD)

-8.34%

Innate Pharma S.A. Share Price Year-To-Date (YTD) return on June 20, 2025: -8.34%

Innate Pharma S.A. Share Price Year-To-Date (YTD) return is -8.34% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Innate Pharma S.A. 52-week low Share Price is USD 2.41 on June 20, 2025, which is 31.32% above the current Share Price.
Innate Pharma S.A. 52-week low Share Price is USD 1.44 on June 20, 2025, which is -21.49% below the current Share Price.
Innate Pharma S.A. average Share Price for the last 52 weeks is USD 2.05.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

Paris Stock Exchange: IPH.PA

Innate Pharma S.A.

CEO	Mr. Jonathan E. Dickinson B.Sc., M.B.A.
IPO Date	Nov. 1, 2006
Location	France
Headquarters	117, Avenue de Luminy
Employees	181
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals 💉 Vaccines

Description

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.